Valeant Pharmaceuticals International Inc. (NYSE: VRX, TSX, VRX) has come back with a $418 million offer for Obagi Medical Products Inc. (Nasdaq: OMPI), topping Merz Pharma Group’s $380 million offer on April 2. 

Obagi’s board of directors unanimously approved Valeant’s amended offer. The deal comes with a $21 million termination fee.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.